Despite their effectiveness as tumor-combating agents, VEGF TKIs can exert a range of adverse effects on cardiovascular and kidney health (Kappers et al., 2009; Perazella, 2012; Estrada et al., 2019; Neves et al., 2020; Dobbin et al., 2021). This evidence concerns the gene VEGFA and neoplasm.